GH
Guardant Health, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+42/100
Last price
169.31
▼ 17.91 (9.57%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
187.16
Prev close
187.22
Day high
191.01
Day low
170.11
Volume
3.39M
Market cap
$22.91B
P/E (TTM)
—
52W range
61.00 – 191.01
Day trading desk
Gap from prior close
-0.03%
Prior close 187.22
VWAP
173.55
-2.44% from price
Relative volume
3.19×
Unusually busy
Session range
15.18%
169.00 – 194.65
Position in range
1%
Near session low
ATR (14D)
8.29
4.90% of price
Prior day high
187.69
PDH
Prior day low
176.37
PDL
Bid / ask spread
—
Quote not published
Session volume
6.42M
Avg 2.01M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.96%
-5.9%
1M
+5.75%
+4.6%
3M
+9.30%
+4.8%
6M
+82.95%
+64.8%
YTD
+67.11%
+52.9%
1Y
+171.63%
+155.2%
3Y
+475.88%
+393.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
10 more panels on GH open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-174.21K
Net selling
Buy transactions
55
726.97K shares
Sell transactions
33
901.17K shares
Net transactions
+88
Buys less sells
Sell : buy shares
1.2 : 1
Mixed
Insider-held shares
5.34M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 21, 26 | MIGNONE ROBERTO A. Director |
— | 264 | — | Direct |
| Sep 17, 26 | HIDALGO MEDINA MANUEL Director |
— | 232 | — | Direct |
| Sep 16, 26 | TARIQ MUSA Director |
SELL | 116 | $20.30K | Direct |
| Sep 16, 26 | AZAR ALEX M II Director |
SELL | 826 | $144.55K | Direct |
| Sep 16, 26 | KROGNES STEVE E Director |
SELL | 6.67K | $1.17M | Direct |
| Sep 15, 26 | TARIQ MUSA Director |
— | 249 | — | Direct |
| Sep 15, 26 | CHUDOVA DARYA Chief Technology Officer |
SELL | 7.74K | $1.38M | Direct |
| Sep 11, 26 | AZAR ALEX M II Director |
— | 1.65K | — | Direct |
| Sep 11, 26 | KALIA KUMUD Chief Technology Officer |
SELL | 4.00K | $632.19K | Direct |
| Aug 26, 26 | ELTOUKHY HELMY A Chief Executive Officer |
STOCK | 30.00K | $0 | Indirect |
| Aug 21, 26 | MIGNONE ROBERTO A. Director |
— | 264 | — | Direct |
| Aug 21, 26 | TALASAZ AMIRALI Chief Executive Officer |
SELL | 37.50K | $6.34M | Indirect |
| Aug 17, 26 | HIDALGO MEDINA MANUEL Director |
— | 232 | — | Direct |
| Aug 17, 26 | TARIQ MUSA Director |
SELL | 116 | $18.15K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BELL MICHAEL BRIAN |
Chief Financial Officer | 51.82K | Conversion of Exercise of derivative security |
CHUDOVA DARYA |
Chief Technology Officer | 70.64K | Sale |
EAGLE CRAIG |
Officer | 72.00K | Conversion of Exercise of derivative security |
ELTOUKHY HELMY A |
Chief Executive Officer | — | Stock Gift |
FREEMAN CHRIS |
Officer | 65.37K | Conversion of Exercise of derivative security |
GADDE VIJAYA V. |
Director | 28.52K | Conversion of Exercise of derivative security |
KALIA KUMUD |
Chief Technology Officer | 39.79K | Sale |
MONROE TERILYN J |
Officer | 22.98K | Conversion of Exercise of derivative security |
SAIA JOHN GOMES |
Officer | 38.99K | Stock Gift |
TALASAZ AMIRALI |
Chief Executive Officer | — | Sale |
Fundamentals
Market cap$22.91B
Enterprise value$23.55B
Revenue (TTM)$1.18B
Gross profit$769.16M
EBITDA$-430.57M
Net income$-453.44M
EPS (TTM)$-3.19
Free cash flow$26.61M
Total cash$1.05B
Total debt$1.70B
Book value / share$-1.67
Shares outstanding134.20M
Float129.48M
Short % of float8.56%
Dividend yield0.00%
Beta (5Y)1.58
Valuation & profitability ratios
Trailing P/E—
Forward P/E-408.42
PEG ratio—
Price / sales—
Price / book—
EV / revenue19.91
EV / EBITDA-54.69
Gross margin65.01%
Operating margin-38.25%
Profit margin-38.33%
Return on equity—
Return on assets-18.07%
Debt / equity—
Current ratio4.03
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $982.02M | $739.02M | $563.95M | $449.54M | +32.9% |
| Operating revenue | $982.02M | $739.02M | $563.95M | $449.54M | +32.9% |
| Cost of revenue | $349.01M | $289.80M | $227.05M | $156.32M | +20.4% |
| Gross profit | $633.01M | $449.22M | $336.90M | $293.21M | +40.9% |
| Research & development | $364.19M | $347.75M | $367.19M | $373.81M | +4.7% |
| Selling, general & admin | $706.07M | $545.06M | $451.03M | $463.78M | +29.5% |
| Total operating expense | $1.07B | $892.81M | $901.62M | $837.59M | +19.9% |
| Operating income | -$437.25M | -$443.59M | -$564.73M | -$544.38M | +1.4% |
| Net interest income | $30.20M | $51.11M | $32.79M | $3.49M | -40.9% |
| Pre-tax income | -$417.54M | -$435.09M | -$478.76M | -$653.45M | +4.0% |
| Tax provision | -$1.26M | $1.28M | $685.00K | $1.14M | -198.4% |
| Net income | -$416.28M | -$436.37M | -$479.45M | -$654.59M | +4.6% |
| Net income to common | -$416.28M | -$436.37M | -$479.45M | -$654.59M | +4.6% |
| Basic EPS | -3.32 | -3.56 | -4.28 | -6.41 | +6.7% |
| Diluted EPS | -3.32 | -3.56 | -4.28 | -6.41 | +6.7% |
| EBIT | -$413.64M | -$432.51M | -$476.19M | -$650.87M | +4.4% |
| EBITDA | -$373.91M | -$390.12M | -$433.31M | -$614.91M | +4.2% |
| Basic shares | 125.37M | 122.75M | 111.99M | 102.18M | +2.1% |
| Diluted shares | 125.37M | 122.75M | 111.99M | 102.18M | +2.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $378.20M | $525.54M | $1.13B | $141.65M | -28.0% |
| Cash & short-term investments | $1.20B | $839.98M | $1.17B | $1.01B | +43.1% |
| Accounts receivable | $132.65M | $106.85M | $83.88M | $97.26M | +24.1% |
| Inventory | $85.88M | $71.08M | $61.95M | $51.60M | +20.8% |
| Total current assets | $1.47B | $1.06B | $1.35B | $1.19B | +38.9% |
| Property, plant & equipment | $304.76M | $279.08M | $302.71M | $341.92M | +9.2% |
| Goodwill & intangibles | $103.18M | $10.05M | $12.27M | $15.02M | +926.6% |
| Total assets | $2.01B | $1.49B | $1.79B | $1.61B | +35.5% |
| Total current liabilities | $302.73M | $225.58M | $205.92M | $193.22M | +34.2% |
| Long-term debt | $1.50B | $1.14B | $1.14B | $1.14B | +31.6% |
| Total debt | $1.71B | $1.34B | $1.35B | $1.37B | +28.0% |
| Total liabilities | $2.11B | $1.63B | $1.63B | $1.55B | +30.0% |
| Retained earnings | -$2.99B | -$2.58B | -$2.14B | -$1.66B | -16.1% |
| Shareholder equity | -$99.31M | -$139.65M | $158.68M | $60.18M | +28.9% |
| Working capital | $1.16B | $829.53M | $1.14B | $998.37M | +40.2% |
| Net tangible assets | -$202.49M | -$149.70M | $146.41M | $45.16M | -35.3% |
| Shares issued | 130.64M | 123.99M | 121.63M | 102.62M | +5.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$416.28M | -$436.37M | -$479.45M | -$654.59M | +4.6% |
| Depreciation & amortisation | $39.74M | $42.39M | $42.88M | $35.96M | -6.3% |
| Stock-based compensation | $166.22M | $140.41M | $90.76M | $94.69M | +18.4% |
| Change in working capital | -$14.43M | -$60.86M | $53.84M | $61.56M | +76.3% |
| Operating cash flow | -$184.76M | -$239.86M | -$324.98M | -$309.46M | +23.0% |
| Capital expenditure | -$48.31M | -$35.09M | -$20.49M | -$77.46M | -37.7% |
| Investing cash flow | -$627.20M | -$261.31M | $840.25M | $149.82M | -140.0% |
| Share buybacks | -$45.01M | $0 | $0 | — | — |
| Financing cash flow | $671.13M | -$996.00K | $477.38M | -$189.09M | +67,482.8% |
| Free cash flow | -$233.07M | -$274.94M | -$345.46M | -$386.92M | +15.2% |
| End cash position | $489.42M | $629.75M | $1.13B | $141.95M | -22.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $334.98M | $301.67M | $281.27M | $265.20M | $232.09M | +11.0% |
| Operating revenue | $334.98M | $301.67M | $281.27M | $265.20M | $232.09M | +11.0% |
| Cost of revenue | $115.95M | $104.92M | $99.49M | $93.59M | $81.20M | +10.5% |
| Gross profit | $219.03M | $196.75M | $181.77M | $171.61M | $150.88M | +11.3% |
| Research & development | $96.53M | $91.04M | $98.26M | $89.96M | $87.45M | +6.0% |
| Selling, general & admin | $251.61M | $227.06M | $204.31M | $180.64M | $169.85M | +10.8% |
| Total operating expense | $348.15M | $318.10M | $302.58M | $270.60M | $257.30M | +9.4% |
| Operating income | -$129.12M | -$121.35M | -$120.81M | -$98.99M | -$106.41M | -6.4% |
| Net interest income | $8.85M | $9.80M | $8.85M | $6.45M | $6.58M | -9.7% |
| Pre-tax income | -$119.96M | -$111.70M | -$130.22M | -$92.59M | -$99.86M | -7.4% |
| Tax provision | $185.00K | $372.00K | -$1.73M | $136.00K | $38.00K | -50.3% |
| Net income | -$120.14M | -$112.08M | -$128.49M | -$92.72M | -$99.90M | -7.2% |
| Net income to common | -$120.14M | -$112.08M | -$128.49M | -$92.72M | -$99.90M | -7.2% |
| Basic EPS | -0.90 | -0.85 | -1.00 | -0.74 | -0.80 | -5.9% |
| Diluted EPS | -0.90 | -0.85 | -1.00 | -0.74 | -0.80 | -5.9% |
| EBIT | -$118.61M | -$110.36M | -$129.04M | -$91.65M | -$98.88M | -7.5% |
| EBITDA | -$109.05M | -$100.91M | -$118.99M | -$82.24M | -$88.84M | -8.1% |
| Basic shares | 132.87M | 131.27M | 128.66M | 124.81M | 124.11M | +1.2% |
| Diluted shares | 132.87M | 131.27M | 128.66M | 124.81M | 124.11M | +1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.05B | $989.29M | $378.20M | $580.01M | $629.14M | +6.5% |
| Cash & short-term investments | $1.05B | $1.10B | $1.20B | $580.01M | $629.14M | -4.5% |
| Accounts receivable | $140.15M | $131.20M | $132.65M | $110.48M | $126.45M | +6.8% |
| Inventory | $105.46M | $83.85M | $85.88M | $90.49M | $84.06M | +25.8% |
| Total current assets | $1.36B | $1.37B | $1.47B | $828.88M | $883.43M | -0.2% |
| Property, plant & equipment | $302.87M | $303.94M | $304.76M | $288.16M | $295.91M | -0.4% |
| Goodwill & intangibles | $102.52M | $102.80M | $103.18M | $8.77M | $9.15M | -0.3% |
| Total assets | $1.91B | $1.92B | $2.01B | $1.28B | $1.33B | -0.2% |
| Total current liabilities | $338.96M | $292.14M | $302.73M | $236.92M | $238.43M | +16.0% |
| Long-term debt | $1.50B | $1.50B | $1.50B | $1.11B | $1.12B | -0.0% |
| Total debt | $1.70B | $1.70B | $1.71B | $1.33B | $1.33B | -0.4% |
| Total liabilities | $2.14B | $2.10B | $2.11B | $1.63B | $1.64B | +1.9% |
| Retained earnings | -$3.23B | -$3.11B | -$2.99B | -$2.87B | -$2.77B | -3.9% |
| Shareholder equity | -$222.87M | -$181.07M | -$99.31M | -$354.47M | -$305.48M | -23.1% |
| Working capital | $1.03B | $1.08B | $1.16B | $591.97M | $645.00M | -4.6% |
| Net tangible assets | -$325.39M | -$283.87M | -$202.49M | -$363.24M | -$314.63M | -14.6% |
| Shares issued | 133.61M | 131.51M | 130.64M | 125.98M | 125.45M | +1.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$120.14M | -$112.08M | -$128.49M | -$92.72M | -$99.90M | -7.2% |
| Depreciation & amortisation | $9.56M | $9.44M | $10.05M | $9.41M | $10.04M | +1.3% |
| Stock-based compensation | $57.73M | $47.61M | $43.19M | $42.81M | $42.46M | +21.3% |
| Change in working capital | -$14.26M | -$23.27M | $32.29M | -$3.14M | -$20.24M | +38.7% |
| Operating cash flow | -$57.78M | -$65.62M | -$26.37M | -$35.41M | -$60.28M | +12.0% |
| Capital expenditure | -$11.76M | -$5.58M | -$27.85M | -$10.35M | -$5.65M | -110.7% |
| Investing cash flow | $101.47M | $699.42M | -$905.07M | -$14.35M | -$10.65M | -85.5% |
| Share buybacks | $0 | $0 | $0 | $0 | $0 | — |
| Financing cash flow | $23.01M | -$21.58M | $732.03M | $4.33M | $1.62M | +206.7% |
| Free cash flow | -$69.54M | -$71.20M | -$54.22M | -$45.76M | -$65.93M | +2.3% |
| End cash position | $1.17B | $1.10B | $489.42M | $689.51M | $735.48M | +6.0% |
Options analytics
Put / call volume
1.13
Put-heavy session
Put / call open interest
1.14
Positioning, not flow
Max pain
170.00
-0.4% from spot
ATM implied vol
58.3%
Nearest strike to spot
Skew (10% OTM)
-2.7%
Calls bid over puts
Call volume
775
Contracts, this expiry
Put volume
879
Contracts, this expiry
Heaviest call OI
180.00
1.83K contracts
Heaviest put OI
150.00
1.73K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.39 | -0.42 | -7.8% |
| Mar 2026 | -0.47 | -0.45 | +5.0% |
| Dec 2025 | -0.47 | -0.50 | -6.5% |
| Sep 2025 | -0.49 | -0.39 | +20.3% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.32 | 17 | $350.30M | +32.1% |
| Next quarter | -0.28 | 17 | $369.19M | +31.3% |
| Current year | -1.47 | 21 | $1.36B | +38.2% |
| Next year | -0.41 | 19 | $1.83B | +35.2% |
Analyst targets & ownership
Mean target$199.84
High target$240.00
Low target$105.00
Implied upside18.03%
Analyst count25
ConsensusSTRONG BUY
Strong buy / Buy5 / 20
Hold0
Sell / Strong sell1 / 0
Held by insiders3.98%
Held by institutions100.95%
Institutions holding800
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
177.39
-4.55% from price
SMA 20
174.25
-2.04% from price
SMA 50
166.63
+2.43% from price
SMA 100
152.22
+11.22% from price
SMA 200
124.73
+36.84% from price
EMA 12
176.41
-4.02% from price
EMA 26
172.78
-2.01% from price
EMA 50
166.21
+1.86% from price
RSI (14)
48.3
Neutral
MACD (12,26,9)
3.63
Hist -0.40
ATR (14)
8.29
4.86% of price
Realised vol 30D
48.3%
Annualised
Bollinger upper
188.77
20, 2σ
Bollinger lower
159.72
20, 2σ
50 / 200 cross
Golden
166.63 vs 124.73
Trend bias
Above 200
+36.84%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.91
Less volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
48.3%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-33.0%
Peak to trough
Max drawdown 5Y
-86.7%
Peak to trough
ATR 14
8.29
4.86% of price
Beta (reported)
1.58
5Y monthly, from filing
Short interest
Shares short
11.02M
Prior 11.19M
Change vs prior
-1.5%
Shorts covering
% of float
8.56%
Normal
% of shares out
8.21%
Against total outstanding
Days to cover
5.7
Crowded exit
Float
129.48M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Sep 9, 26 | UBS | MAINTAINED | Buy | Buy |
| Sep 8, 26 | Rothschild & Co | INITIATED | — | Buy |
| Sep 2, 26 | BTIG | MAINTAINED | Buy | Buy |
| Aug 4, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 4, 26 | Stephens & Co. | MAINTAINED | Overweight | Overweight |
| Aug 4, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Aug 3, 26 | Stifel | MAINTAINED | Buy | Buy |
| Jul 31, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jul 31, 26 | Mizuho | MAINTAINED | Outperform | Outperform |
| Jul 31, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Jul 31, 26 | TD Cowen | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Offering Registrations
S-3ASR · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-28
Corporate Changes & Voting Matters
8-K · 2026-04-27
Offering Registrations
S-8 · 2026-02-20
Corporate Changes & Voting Matters
8-K · 2026-02-19
Corporate Changes & Voting Matters
8-K · 2026-01-12
Headlines
Dow Jones Futures: S&P 500 Hits High As Astera, GE Vernova, Arista Lead Buys, But These Stocks Tumble
Investor's Business Daily · 12m ago
Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma
Business Wire · 1d ago
3 Cash-Burning Stocks with Questionable Fundamentals
StockStory · 2d ago
These IBD 50 Stocks Are Stalled. That Could Be A Good Thing.
Investor's Business Daily · 5d ago
Abbott launches Freenome’s colorectal cancer screening test
MedTech Dive · 6d ago
1 Mid-Cap Stock for Long-Term Investors and 2 We Ignore
StockStory · 7d ago
Coverbase Adds Third-Party Risk Veterans as Enterprise Adoption Accelerates
GlobeNewswire · 8d ago
FDA Advisors Said It Should Approve the Grail Multicancer Blood Test. The Stock Rises Sharply.
Barrons.com · 12d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.